SOPHiA GENETICS Reveals Impressive Q4 Results and 2026 Forecast

SOPHiA GENETICS Preliminary Financial Results for Q4 2025

SOPHiA GENETICS, a leader in AI-powered precision medicine, has disclosed its preliminary unaudited financial results for the fourth quarter and full year of 2025. The company is set to continue its growth trajectory with an optimistic outlook for the upcoming year.

Financial Performance Overview

In Q4 2025, SOPHiA GENETICS reported revenues of at least $21 million, marking a commendable 20% year-on-year increase. The company achieved over 105,000 analyses using its SOPHiA DDM™ platform during this quarter, representing a 16% year-on-year growth in analytical services provided.

For the entire year of 2025, SOPHiA GENETICS recorded revenues of approximately $77 million, up approximately 18% compared to the previous year. Approximately 391,000 analyses were conducted on the SOPHiA DDM™ platform, setting a new company record.

Jurgi Camblong, the current CEO and co-founder of SOPHiA GENETICS, expressed, "2025 has been a remarkable year for SOPHiA GENETICS as we have accelerated our revenue growth and substantially exceeded our new business targets, setting the stage for robust future growth."

Outlook for 2026

Looking ahead, the company projects its revenue for 2026 will range between $92 million and $94 million, which indicates an anticipated growth of about 20% to 22% from 2025. However, the company also expects an adjusted EBITDA loss in the range of $29 million to $32 million for the year. This forecast is built on various growth catalysts, including its liquid biopsy application MSK-ACCESS® powered by SOPHiA DDM™, new market opportunities in the U.S., and a revitalized BioPharma segment.

Executive Transition

In a significant leadership change, SOPHiA GENETICS has announced the promotion of Ross Muken to the position of CEO, effective July 1, 2026. Muken, who currently serves as the President and has been a key executive at the company for the past five years, will succeed Camblong. The transition also sees Camblong shifting to the role of Executive Chairman of the Board.

Muken joined SOPHiA GENETICS in February 2021 as CFO and has played a crucial role in driving market strategies and operational successes. As he takes on the CEO role, he aims to build on the solid foundation established by Camblong, who will remain involved in the company's strategic direction.

Camblong commented on this transition, stating, "Ross has demonstrated exceptional strategic capabilities and operational leadership during the time we've worked together. I am confident that he is the right person to lead the company during this next growth phase and significantly expand our international impact."

Simultaneously, Kevin Puylaert has been appointed as the General Manager of Sales starting January 2026, marking another essential change within the executive team.

Conclusion

With strong Q4 results and a promising forecast for 2026, along with critical leadership transitions, SOPHiA GENETICS is poised for continued expansion in the rapidly evolving precision medicine landscape. As it strengthens its market position and expands its innovative offerings, the company's commitment to leveraging AI in healthcare continues to drive its mission of optimizing patient care across the globe.

For more details about SOPHiA GENETICS and its innovative technologies, visit SOPHiAGENETICS.COM.